Table 3.
Studies investigating concordance of ESR1 mutation between tissue and plasma.
| Reference | Method | Total Mutation Rate | Overall concordance rate (%)* | Positive concordance rate (%)** |
|---|---|---|---|---|
| Schiavon G. (15) | ddPCR | 19/171 (11.1%)§ | 30/31 (97%) | 3/4 (75%) |
| Chu D. (30) | NGS | 9/11 (82%) 3/8 (37.5%)§ |
10/11 (91%) 2/5 (40%) |
8/9 (89%) 0/5 (0%) |
| Yanagawa T. (32) | NGS | 11.3% | 5/5 (100%) | 0/5 (0%) |
| Sefrioui D. (33) | SANGER/ ddPCR |
6/7 (86%) | 5/7 (71.4%) | 4/6 (67%) |
| Takeshita T. (29) | ddPCR | 10/35(29%) | 26/35 (74%) | 1/10 (10%) |
| Lupini L. (34) | COLDPCR | 8/40 (20%) | 3/6 (50%) | 1/4 (25%) |
| Spoerke J. (35) | rtPCR/ BEAMing |
37.2%§ | 22/47 (47%) | 11/36 (31%) |
| Wang P. (36) | ddPCR | 3/43(7%)†
4/35 (11.4%) |
3/5 (60%) | 3/5 (60%) |
*Considering cases that were analyzed in both tissue and plasma samples and were both negative or both mutated.
**Considering cases that were positive for ESR1 mutation in tissue DNA and/or ctDNA and were positive in both tissue and ctDNA.
§prospective cohort.
†primary tumor.
ddPCR, droplet digital polymerase chain reaction; NGS, next generation sequencing.